Form 4: Abbott Laboratories Director Michael F. Roman Reports Acquisition of Common Shares

Director Michael F. Roman reports acquisition of 1,635 common shares of Abbott Laboratories through restricted stock units.

Summary

• Michael F. Roman, a director of Abbott Laboratories, reported a transaction on April 25, 2025.
• He acquired 1,635 common shares without par value through the Abbott Laboratories 2017 Incentive Stock Program.
• These shares were acquired as restricted stock units at a price of $0.
• Following the transaction, Roman directly owns 8,478 common shares.
• The restricted stock units will be paid in Abbott common shares on a one-to-one basis upon separation from service, death, or a change in control.
• The report was signed by Jessica H. Paik, Attorney-in-Fact, on April 29, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing a routine transaction. The acquisition of shares by a director is generally viewed as a slightly positive sign, but it's not a major event.

Positives

• The acquisition of shares by a director can be seen as a positive signal, indicating confidence in the company's future.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of restricted stock units is tied to future events such as separation from service, death, or a change in control.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates a director's acquisition of shares, which is a common occurrence in publicly traded companies.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment, as it reflects a director's investment in the company.

Key Dates

Keywords

Abbott Laboratories, Director, Michael F. Roman, Form 4, Restricted Stock Units, Common Shares, Beneficial Ownership, Incentive Stock Program